VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity

[1]  International Association for the Study of Obesity , 2018, The Grants Register 2019.

[2]  A. McAinch,et al.  Peripheral modulation of the endocannabinoid system in metabolic disease. , 2018, Drug discovery today.

[3]  B. Fiebich,et al.  Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy , 2018, Journal of Neuroinflammation.

[4]  M. Tschöp,et al.  Ghrelin regulation of glucose metabolism , 2018, Peptides.

[5]  M. García-Arencibia,et al.  Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor , 2018, Journal of Neuroinflammation.

[6]  Y. Im,et al.  Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs , 2017, Scientific Reports.

[7]  O. Woolcott,et al.  Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases , 2017, Current Diabetes Reports.

[8]  A. Paiardini,et al.  Betulinic acid is a PPARγ antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis , 2017, Scientific Reports.

[9]  D. Cota,et al.  MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future. , 2017, European journal of endocrinology.

[10]  J. Wish,et al.  Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  P. Tanajak,et al.  Letter to the Editor: Parameters, Characteristics, and Criteria for Defining the Term "FGF21 Resistance". , 2017, Endocrinology.

[12]  M. Doherty,et al.  Elevated Fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid Fenretinide in mice , 2017, Scientific Reports.

[13]  M. Tschöp,et al.  Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice , 2017, Molecular metabolism.

[14]  N. Møller,et al.  Acyl Ghrelin Induces Insulin Resistance Independently of GH, Cortisol, and Free Fatty Acids , 2017, Scientific Reports.

[15]  Simon,et al.  Endocannabinoids and metabolism : past , present and future , 2017 .

[16]  A. Lavecchia,et al.  Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode , 2016, Scientific Reports.

[17]  I. Galve-Roperh,et al.  VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease , 2016, Scientific Reports.

[18]  P. Leung,et al.  Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus , 2016, Medicinal research reviews.

[19]  A. Geerts,et al.  Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease , 2016, Cellular and Molecular Life Sciences.

[20]  G. Appendino,et al.  The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways , 2016, Scientific Reports.

[21]  Shufeng Wang,et al.  Nonerythropoietic Erythropoietin-Derived Peptide Suppresses Adipogenesis, Inflammation, Obesity and Insulin Resistance , 2015, Scientific Reports.

[22]  N. Stefan,et al.  Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes , 2015, Molecular metabolism.

[23]  S. Kliewer,et al.  Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21 , 2015, Trends in Endocrinology & Metabolism.

[24]  R. Seeley,et al.  A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents , 2014, Nature Medicine.

[25]  A. Grey.  Diabetes Medications and Bone , 2015, Current Osteoporosis Reports.

[26]  R. Blanco Sequeiros,et al.  HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction , 2014, Diabetes.

[27]  Travis S. Hughes,et al.  An alternate binding site for PPARγ ligands , 2014, Nature Communications.

[28]  P. López-Jaramillo,et al.  The role of leptin/adiponectin ratio in metabolic syndrome and diabetes , 2014, Hormone molecular biology and clinical investigation.

[29]  B. Raaka,et al.  Erythropoietin Signaling: A Novel Regulator of White Adipose Tissue Inflammation During Diet-Induced Obesity , 2014, Diabetes.

[30]  Jaspinder Kaur.  A Comprehensive Review on Metabolic Syndrome , 2014, Cardiology research and practice.

[31]  M. H. Rabinowitz,et al.  Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. , 2013, Journal of medicinal chemistry.

[32]  K. Borch-Johnsen.  Epidemiology of the Metabolic Syndrome , 2013 .

[33]  S. Kliewer,et al.  FGF21 contributes to neuroendocrine control of female reproduction , 2013, Nature Medicine.

[34]  H. Beck-Nielsen.  The metabolic syndrome : pharmacology and clinical aspects , 2013 .

[35]  Leandro Martínez,et al.  Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists , 2012, PloS one.

[36]  M. J. Chalmers,et al.  Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism. , 2012, Structure.

[37]  C. Kahn,et al.  The differential role of Hif1β/Arnt and the hypoxic response in adipose function, fibrosis, and inflammation. , 2011, Cell metabolism.

[38]  O. Gavrilova,et al.  Disruption of Hypoxia-Inducible Factor 1 in Adipocytes Improves Insulin Sensitivity and Decreases Adiposity in High-Fat Diet–Fed Mice , 2011, Diabetes.

[39]  S. Gortmaker,et al.  Health and economic burden of the projected obesity trends in the USA and the UK , 2011, The Lancet.

[40]  Brian D. Weitzner,et al.  Real-Time PyMOL Visualization for Rosetta and PyRosetta , 2011, PloS one.

[41]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[42]  K. Morikawa,et al.  The nuclear receptor PPARγ individually responds to serotonin‐ and fatty acid‐metabolites , 2010, The EMBO journal.

[43]  B. Lecka-Czernik.  Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis , 2010, Current osteoporosis reports.

[44]  C. Rosen.  Revisiting the rosiglitazone story--lessons learned. , 2010, The New England journal of medicine.

[45]  A. Xu,et al.  Adipose Tissue-specific Inhibition of Hypoxia-inducible Factor 1α Induces Obesity and Glucose Intolerance by Impeding Energy Expenditure in Mice* , 2010, The Journal of Biological Chemistry.

[46]  M. Eijken,et al.  A New Concept Underlying Stem Cell Lineage Skewing That Explains the Detrimental Effects of Thiazolidinediones on Bone , 2010, Stem cells.

[47]  I. Hassinen,et al.  Hearts of Hypoxia-inducible Factor Prolyl 4-Hydroxylase-2 Hypomorphic Mice Show Protection against Acute Ischemia-Reperfusion Injury* , 2010, The Journal of Biological Chemistry.

[48]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[49]  S. Kliewer,et al.  Fibroblast growth factor 21: from pharmacology to physiology. , 2010, The American journal of clinical nutrition.

[50]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[51]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[52]  A. Stofkova.  Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. , 2009, Endocrine regulations.

[53]  A. Attie,et al.  Hypoxia-Inducible Factor 1α Induces Fibrosis and Insulin Resistance in White Adipose Tissue , 2009, Molecular and Cellular Biology.

[54]  F. Ashcroft,et al.  PVHL is a regulator of glucose metabolism and insulin secretion in pancreatic beta cells. , 2008, Genes & development.

[55]  Peter Tontonoz,et al.  Fat and beyond: the diverse biology of PPARgamma. , 2008, Annual review of biochemistry.

[56]  A. Peri,et al.  Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells , 2007, Journal of endocrinological investigation.

[57]  Olivier Michielin,et al.  Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. , 2007, Biochimica et biophysica acta.

[58]  M. Matsuda,et al.  Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation , 2007, Diabetes.

[59]  M. Hyman,et al.  Molecular regulation of the PAI‐1 gene by hypoxia: contributions of Egr‐1, HIF‐1 α, and C/EBPα , 2007 .

[60]  M. Hyman,et al.  Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha. , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  P. Pérez-Martínez,et al.  Dietary fat, genes and insulin sensitivity , 2007, Journal of Molecular Medicine.

[62]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[63]  J. Lehmann,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society Divergent Effects of Selective Peroxisome Proliferator- Activated Receptor-�2 Ligands on Adipocyte Versus Osteoblast Differentiation , 2022 .

[64]  J. Lehmann,et al.  Divergent Effects of Selective Peroxisome Proliferator-Activated Receptor- (cid:1) 2 Ligands on Adipocyte Versus Osteoblast Differentiation , 2002 .

[65]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.